Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients (Childbenox)
Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Weight Heparin in Child-Pugh B Cirrhotic Patients: a Randomized Controlled Study
Sponsor: Assistance Publique - Hôpitaux de Paris
Suspended
Premature discontinuation of inclusions by the sponsor for low inclusion
A PHASE3 clinical study on Cirrhosis, this trial is suspended. The trial is conducted by Assistance Publique - Hôpitaux de Paris and has accumulated 6 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Suspended PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Suspended PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
▶ Show 1 earlier version
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE3
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .